Advertisement

Pharmaceutisch Weekblad

, Volume 8, Issue 1, pp 53–59 | Cite as

The quinolones in chronic bronchitis

  • B. I. Davies
  • F. P. V. Maesen
  • J. P. Teengs
  • C. Baur
Quinolones in Perspective

Abstract

Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients). In general, good clinical results were observed in 50–70% of the patients treated, most failures being due to relapses or reinfections withStreptococcus pneumoniae orPseudomonas aeruginosa. Studies on blood and sputum concentration suggested that gastro-intestinal absorption was not always satisfactory. Unwanted drug effects were noted with all agents studied, generally presenting as stomach pain, nausea, hallucinations, or dizziness. Most adverse drug reactions were seen with enoxacin, often but not always during concomitant treatment with theophylline.

Key words

Bronchitis Drug evaluation Drug interactions Minimum inhibitory concentrations Pharmacokinetics Quinolones Side effects Theophylline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davies BI, Maesen FPV. The diagnosis and treatment of respiratory infections. In: Brumfitt W, Hamilton-Miller JMT, eds. A clinical approach to progress in infectious diseases. Oxford: Oxford University Press, 1983:132–58.Google Scholar
  2. 2.
    Bauernfeind A, Petermüller C.In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111–5.Google Scholar
  3. 3.
    Muytjens H, Van der Ros-van de Repe J, Van Veldhuizen G. Comparative activities of ciprofloxacin (Bay 09867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Chemother 1983;24:302–4.Google Scholar
  4. 4.
    Barry AL, Jones RN. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin and oxolinic acid afterin vitro selection of resistant populations. Antimicrob Agents Chemother 1984;25:775–7.Google Scholar
  5. 5.
    Wise R. The activity of quinolones against respiratory tract pathogenes. Quinolones Bull June 1985;1:1–2.Google Scholar
  6. 6.
    Davies BI, Maesen FPV, Teengs JP. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother 1984;14(suppl 0):83–9.Google Scholar
  7. 7.
    Maesen FPV, Davies BI, Teengs JP. Pefloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1985;16:379–88.Google Scholar
  8. 8.
    Davies BI, Maesen FPV, Baur C, Teengs JP, Cremer HMHG. Ciprofloxacin in purulent exacerbations of chronic bronchitis: a clinical microbiological and pharmacokinetic study. 14th International Congress of Chemotherapy. Kyoto. June 23–28. 1985. Kyoto: International Society of Chemotherapy, 1985:abstract S 50-3.Google Scholar
  9. 9.
    Mulder J, Goslings WRO, Van der Plas MC, Lopez Cardozo P. Studies on the treatment with antibacterial drugs of acute and chronic bronchitis caused byHaemophilus influenzae. Acta Med Scand 1952;143:32–49.Google Scholar
  10. 10.
    Davies BI, Maesen FPV; Brouwers J. Cefoperazone in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1982;9:149–55.Google Scholar
  11. 11.
    Davies BI, Maesen FPV. Serum and sputum antibiotic levels after ampicillin. amoxycillin and bacampicillin in chronic bronchitis patients. Infection 1979;7(suppl 5):S465–8.Google Scholar
  12. 12.
    Davies BI, Maesen FPV, Brombacher PJ, Sjövall J. Twice daily dosage of bacampicillin in chronic bronchitis: a double blind study. Scand J Respir Dis 1978;59:249–56.Google Scholar
  13. 13.
    Wijnands WJA, Van Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984;2:108.Google Scholar
  14. 14.
    Maesen FPV, Teengs JP, Baur C, Davies BI. Quinolones and raised plasma concentrations of theophylline. Lancet 1984;2:530.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1986

Authors and Affiliations

  • B. I. Davies
    • 1
  • F. P. V. Maesen
    • 2
  • J. P. Teengs
    • 2
  • C. Baur
    • 2
  1. 1.Department of Medical MicrobiologyDe Wever HospitalCX HeerlenThe Netherlands
  2. 2.Department of Respiratory DiseasesDe Wever HospitalCX HeerlenThe Netherlands

Personalised recommendations